Business News

RRDonnelley-073014-lg.jpgPrint and related services provider R.R. Donnelley & Sons Co. Wednesday reported lower second-quarter net profit, despite sales growth of about 13 percent. The company also backed its sales outlook for full year 2014.

Sanofi And Regeneron: 9 Phase 3 ODYSSEY Trials Of Alirocumab Met Primary Goal

French drug maker Sanofi (SNYNF, SNY) and U.S.-based Regeneron Pharmaceuticals, Inc. (REGN) announced Wednesday that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint. According to the companies, the primary goal was of a greater...

Heartland Payment Systems To Buy TouchNet Information Systems

Oando Energy Resources Completes Purchase Of ConocoPhillips Nigerian Oil And Gas Business For $1.5 Bln

EGain Signd Definitive Agreement To Acquire Exony

Solera Holdings Completes Acquisition Of Insurance And Services Division Of Pittsburgh Glass Works, LLC


PGT Inc. (PGTI) Rose To A 2-Month High After Q2 Profit Exceeded Expectations

PGT Inc. (PGTI) reported second quarter EPS of $0.16 Tuesday morning, up from $0.14 a year ago. The consensus estimate was for EPS of $0.12. PGT gapped open dramatically higher Tuesday, but traded in a range for the majority of the session. The stock ended the day with a gain of 2.02 at $9.41 on strong...

ContraFect Prices IPO At $6.00 Per Unit

ContraFect Corp. (CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced the pricing of its initial public offering of 6 million units priced at $6.00 per unit for total gross proceeds of $36 million. The offering was priced...